Literature DB >> 14556921

Gene promoter hypermethylation in oral rinses of leukoplakia patients--a diagnostic and/or prognostic tool?

M López1, J M Aguirre, N Cuevas, M Anzola, J Videgain, J Aguirregaviria, M Martínez de Pancorbo.   

Abstract

Leukoplakia is the most frequent oral precancerous lesion and shows a variable rate of malignant transformation. We hypothesised that the detection of molecular alterations, like the promoter hypermethylation of DNA, in oral cytological samples from patients at risk of developing primary or recurrent tumours could be a valuable diagnostic and prognostic tool in the management of these lesions. Two groups of patients with differing risks of developing oral squamous cell carcinoma (OSCC) were analysed. DNA was extracted from the oral rinse of each patient. The methylation status of the p16, p14 and MGMT gene promoters was determined using a methylation-specific polymerase chain reaction (MSP). Methylation of p16 and MGMT was observed in 44 and 56% of the oral samples, respectively. Only 12% of the cases showed p14 methylation. DNA hypermethylation was more frequent in patients with previous OSCC. DNA promoter hypermethylation is frequent during early oral carcinogenesis and even more so in the later stages. MSP using oral rinses is a non-invasive and highly sensitive technique which could be used to monitor patients with precancerous and cancerous oral lesions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14556921     DOI: 10.1016/s0959-8049(03)00550-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

1.  DAPK promoter hypermethylation in tissues and body fluids of oral precancer patients.

Authors:  Yang Liu; Zeng-Tong Zhou; Qing-Bo He; Wei-Wen Jiang
Journal:  Med Oncol       Date:  2011-04-24       Impact factor: 3.064

Review 2.  Epigenetic mechanisms in oral carcinogenesis.

Authors:  Jacqueline A Gasche; Ajay Goel
Journal:  Future Oncol       Date:  2012-11       Impact factor: 3.404

3.  Anatomic site based ploidy analysis of oral premalignant lesions.

Authors:  M N Islam; L Kornberg; E Veenker; D M Cohen; I Bhattacharyya
Journal:  Head Neck Pathol       Date:  2009-11-24

Review 4.  DNA methylation in tumour and normal mucosal tissue of head and neck squamous cell carcinoma (HNSCC) patients: new diagnostic approaches and treatment.

Authors:  Nongnit Laytragoon-Lewin; Lars Erik Rutqvist; Freddi Lewin
Journal:  Med Oncol       Date:  2013-07-04       Impact factor: 3.064

5.  Methylation analysis of cancer-related genes in non-neoplastic cells from patients with oral squamous cell carcinoma.

Authors:  Melissa de Freitas Cordeiro-Silva; Zilda Fagundes Lima Oliveira; José Roberto Vasconcelos de Podestá; Sonia Alves Gouvea; Sandra Ventorin Von Zeidler; Iúri Drumond Louro
Journal:  Mol Biol Rep       Date:  2011-03-05       Impact factor: 2.316

6.  Promoter hypermethylation profile of tumour suppressor genes in oral leukoplakia and oral squamous cell carcinoma.

Authors:  G S Asokan; S Jeelani; N Gnanasundaram
Journal:  J Clin Diagn Res       Date:  2014-10-20

7.  Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer.

Authors:  Wojciech K Mydlarz; Patrick T Hennessey; Joseph A Califano
Journal:  Expert Opin Med Diagn       Date:  2010-01-01

8.  Altered histone mark deposition and DNA methylation at homeobox genes in human oral squamous cell carcinoma.

Authors:  Katarzyna M Marcinkiewicz; Lorraine J Gudas
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

9.  Novel DNA methylation targets in oral rinse samples predict survival of patients with oral squamous cell carcinoma.

Authors:  Scott M Langevin; Rondi A Butler; Melissa Eliot; Michael Pawlita; Jennifer Z J Maccani; Michael D McClean; Karl T Kelsey
Journal:  Oral Oncol       Date:  2014-09-18       Impact factor: 5.337

10.  Methylation-mediated molecular dysregulation in clinical oral malignancy.

Authors:  Rebecca Towle; Cathie Garnis
Journal:  J Oncol       Date:  2012-05-07       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.